The partnership follows a year of explorative collaboration and research leading to promising preliminary results. It will focus on specific R&D and biomanufacturing projects.
In R&D, Glaxo and Imec will explore how nanotechnology can accelerate the development and production of new vaccines through disruptive highly parallelized solutions.
In biomanufacturing, nanotechnology will be used to automate and improve control of manufacturing processes.
Glaxo and Imec are currently working together on several projects that arose from Makeathon workshops organised by Glaxo.
These workshops allow experts from both organizations to interact and focus on specific interdisciplinary challenges to conceive new, high-impact products for the future of vaccine development and bio-manufacturing